Cadrenal Therapeutics acquires VLX-1005, a Phase 2 12-LOX inhibitor for HIT, from Veralox

Cadrenal Therapeutics, Inc.

Acquisition closed Dec 10, 2025; upfront cash $200K plus milestone payments up to $15M and 5% royalties on net sales.
VLX-1005 is a first-in-class, potent 12-LOX inhibitor with FDA Orphan Drug and Fast Track designations for HIT.
Phase 2 interim results demonstrated encouraging reductions in thromboembolic events; no deaths or serious AEs in Phase 1.
HIT affects ~56,000 confirmed diagnoses annually in the U.S.; current therapies do not address immune-driven pathogenesis.
Deal adds VLX-1005 to Cadrenal's anticoagulation pipeline alongside tecarfarin and frunexian, targeting $3B+ peak revenue potential.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cadrenal Therapeutics, Inc. entered into Asset Purchase Agreement with Veralox Therapeutics Inc. valued at $200,000 (effective 2025-12-10).

Action: entry
Agreement: asset purchase
Counterparty: Veralox Therapeutics Inc.
Value: $200,000
Effective: 2025-12-10

Exact text from the filing

On December 10, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Veralox Therapeutics Inc., a Delaware corporation (“Seller”)

View on SEC.gov

Browse all material agreements →

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-120360

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.